MirageC/Moment via Getty Images Evaluating MannKind's Position in Light of Recent Tyvaso DPI Sale MannKind (NASDAQ:MNKD) is down 14% since my "Buy" recommendation in October. This is in spite of favorable advancements. In January, MannKind sold 10% of its Tyvaso DPI, developed in collaboration with United Therapeutics (UTHR), for $150 million upfront (with the potential for an additional $50 million depending on Tyvaso DPI revenue) to Sagard Healthcare. The milestone payment is outlined as follows: $50  ...